In Women With TPF3-Mutated, Platinum Sensitive Ovarian Cancer, WEE1 Kinase Inhibitor, Plus Carboplatin, Paclitaxel Improved PFS Compared With Chemo Alone
Cancer Therapy Advisor (7/8, Lawrence) reports, “Adavosertib, a WEE1 kinase inhibitor, plus carboplatin and paclitaxel improved progression-free survival (PFS) in women with TP53-mutated, platinum-sensitive ovarian cancer compared with chemotherapy alone, according to results from a phase 2 study.” The researchers found “the overall response rate with adavosertib was 75% vs 69% with chemotherapy alone,” while “rate of complete response for adavosertib was 11.9% compared with 8.9% with chemotherapy alone.” The findings were published in Clinical Cancer Research.